|
A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer. |
|
|
Stock and Other Ownership Interests - C2i genomics |
Consulting or Advisory Role - Checkmate Pharmaceuticals; Lilly; Natera; Pfizer; Roche/Genentech |
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); PMV Pharma; PureTech (Inst) |
|
|
Honoraria - Bayer; Celgene; Lilly |
Consulting or Advisory Role - Celgene; Ipsen; Merrimack |
Research Funding - Abbvie; Actuate Therapeutics; AstraZeneca; Bayer; Celgene; Dicephera Pharmaceuticals, Inc.; Genentech/Roche; Gilead Sciences; Halozyme; Ipsen; Lilly; Millennium; Novartis |
Travel, Accommodations, Expenses - Bayer; Celgene; Lilly |
|
Lawrence Scott Blaszkowsky |
Stock and Other Ownership Interests - Pfizer (I) |
|
|
Stock and Other Ownership Interests - Biogen; Merck |
Consulting or Advisory Role - Foundation Medicine |
Research Funding - Genentech/Roche (Inst) |
|
|
Leadership - PanTher Therapeutics |
Stock and Other Ownership Interests - PanTher Therapeutics; ROME Therapeutics; TellBio |
Consulting or Advisory Role - Foundation Medicine; Millipore; NanoString Technologies; Pfizer; ROME Therapeutics; Third Rock Ventures |
Research Funding - ACD Biotechne (Inst); PureTech (Inst); Ribon Therapeutics (Inst) |
Patents, Royalties, Other Intellectual Property - Patent License to PanTher Therapeutics (Inst); Patent License to TellBio Inc. (Inst); Patent licensed to Rome Therapeutics by my Institution. (Inst) |
|
|
Stock and Other Ownership Interests - Abata Therapeutics; Asher Biotherapeutics |
Honoraria - Checkmate Pharmaceuticals |
Consulting or Advisory Role - Abata Therapeutics; Asher Biotherapeutics; BioNTech; Checkmate Pharmaceuticals; Rheos Medicines; Third Rock Ventures; venBio |
|
|
Consulting or Advisory Role - AIM Specialty Health; Asahi Kasei; Astellas Pharma; BASF; Helsinn Therapeutics; HERON; Napo Pharmaceuticals; Oragenics; Oragenics; Pfizer/EMD Serono; Vector Oncology |
Expert Testimony - Regents of the University of California |
|
|
Stock and Other Ownership Interests - Acworth Pharmaceuticals; Exact Sciences; MPM Capital; Thrive Earlier Detection Corp |
Honoraria - Research to Practice; UpToDate |
Consulting or Advisory Role - Gritstone Bio; Innocrin Pharma; Maverick Therapeutics; MPM Capital; Oncorus; TCR2 Therapeutics; Twentyeight-Seven Therapeutics |
Research Funding - Stand up to Cancer (Inst) |
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties |
Expert Testimony - Boehringer Ingelheim |
Other Relationship - TCR2 Therapeutics |
|
|
No Relationships to Disclose |
|
|
Research Funding - Pfizer (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Taiho Pharmaceutical |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - PanTher Therapeutics |
Consulting or Advisory Role - Boston Scientific; Merck; Novocure; Syndax; Synthetic Biologics |
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); IntraOp (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst) |